Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Children's asthma drug not beneficial enough - NICE

  • Comment

The asthma drug omalizumab (Xolair) does not produce enough benefits in children under 12 to justify it being prescribed by the NHS, the National Institute for Health and Clinical Excellence has ruled.

NICE assessed the drug for 6 to 11-year-olds with severe persistent allergic asthma but concluded it offered limited benefits compared with other available treatments.

However, NICE said children currently receiving omalizumab should continue with it until an appropriate time to stop.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs